More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.89B
EPS
-4.69
P/E ratio
--
Price to sales
385.49
Dividend yield
--
Beta
1.912294
Previous close
$40.37
Today's open
$40.11
Day's range
$39.80 - $41.17
52 week range
$39.80 - $63.45
show more
CEO
Samarth Kulkarni
Employees
278
Headquarters
Zug,
Exchange
NASDAQ Global Market
Shares outstanding
97000813
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
CRISPR Therapeutics NASDAQ: CRSP is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY.
MarketBeat • Nov 17, 2026

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research • Nov 17, 2026

CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 10:00 a.m. GMT. A live webcast of the fireside chat will be available on the “Events & Presentations” page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
GlobeNewsWire • Nov 10, 2026

Crispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish Sentiment
Crispr Therapeutics remains a market leader in gene-editing, with Casgevy and a robust pipeline targeting hematology, cardiovascular, autoimmune, and regenerative medicine. CRSP's revenue growth from Casgevy has been slower than anticipated, but operational momentum and expanded patient access are improving the long-term outlook. Early-stage data for CTX310 in cardiovascular disease show promising, durable efficacy and safety, positioning CRSP ahead of competitors in gene-editing therapies.
Seeking Alpha • Nov 10, 2026

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG), who had a median baseline TG level above 1,000 mg/dL- -CTX310 was well tolerated, with no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases- ZUG, Switzerland and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today presented clinical data from its Phase 1b clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting angiopoietin-like protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia (sHTG). A single-course treatment with CTX310 produced mean reductions from baseline at Day 30 of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) in participants with a median baseline TG level above 1,000 mg/dL.
GlobeNewsWire • Nov 9, 2026

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response
GlobeNewsWire • Nov 8, 2026

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Nov 6, 2026

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12 to 15, 2026.
GlobeNewsWire • Nov 4, 2026

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
Zacks Investment Research • Nov 3, 2026

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older – – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C – – Phase 1b data for CTX310 in severe hypertriglyceridemia to be presented in a late-breaking oral presentation at AHA Scientific Sessions 2026; Phase 1 data for zugo-cel in systemic sclerosis to be presented at ACR Convergence 2026 – – Completed enrollment in the Phase 2 clinical trial of CTX611 in patients undergoing total knee arthroplasty – – Appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer and A.J.
GlobeNewsWire • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell CRISPR Therapeutics AG commission-free¹. Build wealth for the long term using automated trading and transfers.